Wisconsin Alumni Research Foundation
This article was originally published in Start Up
Executive SummaryFounded in 1925 to administer the vitamin D patent portfolio of University of Wisconsin, Madison professor Harry Steenbock, the Wisconsin Alumni Research Foundation was considered a model for the Bayh-Dole Act, which gave institutions title and rights to their federally funded inventions, and also the responsibility to actively commercialize them, consistent with the public interest. WARF's licensing activities have included the development of blood anti-coagulants, leading to Coumadin, another generation of patents on pharmaceutical use of vitamin D analogs, and the medical imaging technology digital subtraction angiography. Since the passage of Bayh-Dole, WARF has added to its licensing portfolio, among other inventions, MRI imaging techniques, the so-called "UW Solution" for preserving organs for transplantation, and core patents on the use of primate and human embryonic stem cells.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.